Remdesivir for COVID-19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature

Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID-19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such pa...

Full description

Saved in:
Bibliographic Details
Published inClinical Case Reports Vol. 10; no. 2
Main Authors Ahmad Al Bishawi, Hamad Abdel Hadi, Elmekaty, Eman, Musaed Al Samawi, Nair, Arun, Mohammed Abou Kamar, Muna Al Maslamani, Abdelmajid, Alaaeldin
Format Report
LanguageEnglish
Published Hoboken John Wiley & Sons, Inc 01.02.2022
Online AccessGet full text

Cover

More Information
Summary:Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID-19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.
DOI:10.1002/ccr3.5467